2015-03-16T17:30:57-05:00 2014-06-30 860683059 BEACHFLEISCHMAN PC PO BOX 64130 TUCSON AZ 857284130 990 2013-07-01 201991334 CRITICAL PATH INSTITUTE CRIT 5205473440 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 STEVEN BROADBENT MBA COO 5205473440 2015-03-12 1 KAREN K MCCLOSKEY CPA P00099644 5203214600 2013 2016-03-07 17:11:31Z MARTHA BRUMFIELD PHD 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 8449378 0 X WWW.C-PATH.ORG X 2004 AZ FOSTER AND CONDUCT RESEARCH AND EDUCATIONAL PROGRAMS THAT WILL LEAD TO SAFER MEDICAL PRODUCTS. 13 12 42 0 0 0 5915630 5370782 2977903 3007261 2525 -13826 311 52598 8896369 8416815 778641 293808 0 0 4200117 4027055 0 0 54204 4370872 3713997 9349630 8034860 -453261 381955 8716861 15253096 5205240 11359520 3511621 3893576 X THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. 0 0 6437786 293808 3007261 THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO IMPLEMENTING THE FDA'S CRITICAL PATH INITIATIVE BY CREATING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA AND EMA) THE REGULATED (MEDICAL PRODUCT INDUSTRY), ACADEMIA, PATIENTS ORGANIZATIONS, AND OTHER ORGANIZATIONS THAT RESULT IN ACCELERATED DEVELOPMENT OF SAFE, NEW MEDICAL PRODUCTS, AND SERVES AS A RESOURCE TO CONGRESS. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR REPORT INCLUDE:THE COALITION AGAINST MAJOR DISEASES (CAMD) DEVELOPS TOOLS AND PROCESSES TO ACCELERATE PROGRESS IN THE PREVENTION, TREATMENT AND CURE OF MAJOR NEURODEGENERATIVE DISEASES, INITIALLY FOCUSING ON ALZHEIMER'S AND PARKINSON'S DISEASES. ACCOMPLISHMENTS INCLUDE: 1) A PUBLIC DATABASE OF ALZHEIMER'S DISEASE CLINICAL TRIALS CONTINUES TO GROW IN SIZE AND USE. DATA FROM TWENTY FOUR CLINICAL TRIALS OF MEMBER COMPANIES COMPRISING 6,500 PATIENTS HAVE BEEN REMAPPED INTO THE NEW DATA STANDARD. THE DATABASE IS BEING USED BY NEARLY 250 SCIENTISTS FROM AROUND THE WORLD. 2) A DISEASE PROGRESSION MODEL CREATED FROM USE OF THE DATA FROM THE DATABASE, AND DATA FROM THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE STUDIES. THE MODEL, ALONG WITH A SIMULATION INFRASTRUCTURE, HAS BEEN FORMALLY ENDORSED BY THE FDA AND EMA FOR USE IN DESIGNING CLINICAL TRIALS FOR ALZHEIMER'S DISEASE. 3) A SERIES OF CEREBRAL SPINAL FLUID (CSF) AND HIPPOCAMPAL IMAGING BIOMARKERS WHICH HAVE BEEN STUDIED FOR USE IN IDENTIFYING EARLY SYMPTOMATIC PATIENTS WITH A HIGH LIKELIHOOD OF PROGRESSION TO DEMENTIA IN A SHORT PERIOD OF TIME. SUCH PATIENTS WOULD BE INCLUDED IN CLINICAL TRIALS OF THERAPIES FOR ALZHEIMER'S DISEASE. 4) LOW HIPPOCAMPAL VOLUME HAS BEEN QUALIFIED BY THE EUROPEAN MEDICINES AGENCY (EMA), AND A RESEARCH PLAN FOR BOTH SETS OF BIOMARKERS HAS BEEN SUBMITTED TO THE FDA. CAMD MEMBERS HAVE MET WITH AND RECEIVED FEEDBACK FROM THE FDA, HAVE RESPONDED TO THEIR QUESTIONS AND ARE NOW EXECUTING THE RESEARCH PLAN. 5) THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) STANDARD FOR PARKINSON'S DISEASE HAS BEEN DEVELOPED AND PUBLISHED AND IS AVAILABLE FOR USE. 6) AN UPDATED VERSION OF THE ALZHEIMER'S DISEASE CDISC STANDARD WAS DEVELOPED TO INCLUDE DATA ELEMENTS FOR PRE-DEMENTIA, ADDITIONAL COGNITIVE SCALES, AND ADDITIONAL BIOMARKERS. 7) A BRIEFING PACKAGE FOR SPECT IMAGING OF DOPAMINE TRANSPORT ACTIVITY FOR USE AS A CLINICAL TRIAL ENRICHMENT CRITERION FOR PARKINSON'S DISEASE HAS BEEN SUBMITTED TO THE FDA FOR ADVICE. 8) A BRIEFING PACKAGE HAS BEEN SUBMITTED IN THE PROCESS OF DEVELOPING AND QUALIFYING AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT FOR EARLY STAGES OF ALZHEIMER'S DISEASE.THE PATIENT-REPORTED OUTCOME CONSORTIUM (PRO) WAS CREATED TO IDENTIFY AND PRIORITIZE THE MEDICAL PRODUCT DEVELOPMENT AREAS WHERE PRO INSTRUMENTS ARE NEEDED, AS WELL AS TO SUBMIT QUALIFICATION DOSSIERS TO REGULATORY AGENCIES FOR QUALIFICATION OF PRO INSTRUMENTS FOR USE IN REGULATORY AND DRUG DEVELOPMENT DECISION MAKING. THE FOLLOWING WORKING GROUPS ARE IN THE PROCESS OF DEFINING PLANS AND ADJUSTING BUDGETS FOR ITS QUANTITATIVE PILOT STUDY: ASTHMA WORKING GROUP, DEPRESSION WORKING GROUP, AND IRRITABLE BOWEL SYNDROME WORKING GROUP. TWO WORKING GROUPS, FUNCTIONAL DYSPEPSIA AND NON-SMALL CELL LUNG CANCER ARE CONTINUING THE WORK TO COMPLETE THE QUALITATIVE RESEARCH PHASE OF EACH PROJECT. THE COGNITION WORKING GROUP IS ABOUT TO BEGIN ITS WORK ON THE NEXT PHASE TO FURTHER DEVELOP, REFINE, AND EVALUATE THE DRAFT TO SUPPORT THE REGULATORY QUALIFICATION PROCESS. THE RHEUMATOID ARTHRITIS WORKING GROUP AWAITS THE RESULTS OF THE LITERATURE REVIEW CONDUCTED BY OMERACT IN ORDER TO INFORM ITS NEXT STEP OF THE PROJECT.THE PREDICTIVE SAFETY TESTING CONSORTIUM (PSTC) COMPILES, GENERATES, AND SUBMITS FOR REGULATORY REVIEW DATA ON NEW SAFETY BIOMARKERS TO BE USED IN DRUG DEVELOPMENT, THUS ADVANCING THE DRUG SAFETY ASSESSMENT PROCESS. THE FDA AND EMA HAVE ISSUED "LETTERS OF SUPPORT" ON THE KIDNEY SAFETY BIOMARKERS TO ENCOURAGE THEIR USE AND DATA COLLECTION FOR ULTIMATE CLINICAL QUALIFICATION. STUDIES ARE ONGOING TO MONITOR THE BIOMARKERS' PERFORMANCE IN PATIENTS WHO ARE ALREADY BEING MONITORED DUE TO NECESSARY TREATMENT WITH POTENTIALLY TOXIC THERAPIES AND ARE BEING RUN IN CONJUNCTION WITH THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH. THE SKELETAL MUSCLE WORKING GROUP HAS COMPLETED THEIR RESEARCH AND EVALUATION AND IS PREPARING TO PRESENT THEIR INFORMATION TO THE FDA TO GARNER A LETTER OF SUPPORT. WORK IS ALSO UNDERWAY TO ASSESS THE VALUE OF PRECLINICAL BIOMARKERS TO DETECT DRUG INDUCED INJURY IN THE LIVER, VASCULAR AND TESTICULAR SYSTEMS, AND DRUG INDUCED CARDIAC HYPERTROPHY.THE CRITICAL PATH TO TB REGIMENS (CPTR) IS A COLLABORATION WITH THE BILL AND MELINDA GATES FOUNDATION AND THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT. THE GOAL OF THIS COLLABORATION IS TO SIGNIFICANTLY SPEED DEVELOPMENT OF INNOVATIVE TREATMENT REGIMENS FOR TUBERCULOSIS. THE BIOMARKER AND CLINICAL ENDPOINT WORKING GROUP MET WITH THE FDA, AND WITH FDA'S SUPPORT AND ENCOURAGEMENT, ARE WORKING TO INCLUDE THE USE OF QUANTITATIVE LIQUID CULTURE RESULTS FOR DETERMINING TREATMENT SUCCESS OR FAILURE IN THE TB THERAPY DEVELOPMENT GUIDANCE. THE EMA SAWP HAS ISSUED A POSITIVE OPINION ABOUT A HOLLOW FIBER MODEL FOR USE TO SELECT DRUG REGIMENS, AND INFORM DOSING DECISIONS. WORK IS ONGOING TO HELP DEVELOP A RAPID DRUG SENSITIVITY TEST TO AID IN INFORMING APPROPRIATE TREATMENT DECISIONS FOR PATIENTS THAT HAVE DRUG RESISTANT FORMS OF TB. SEVERAL NEW TB MODELING EFFORTS WERE LAUNCHED THIS YEAR FROM A PHYSIOLOGICALLY-BASED PHARMACODYNAMIC MODEL TO A POPULATION-BASED DISEASE PROGRESSION MODEL TO AID IN THE UNDERSTANDING THE DISEASE AND FACILITATE THE DESIGN OF NEW CLINICAL TRIALS.A PARTNERSHIP WITH THE POLYCYSTIC KIDNEY DISEASE (PKD) FOUNDATION TO QUALIFY TOTAL KIDNEY VOLUME AS A PROGNOSTIC BIOMARKER FOR PKD HAS MADE SIGNIFICANT PROGRESS. THE CDISC DATA STANDARD IS COMPLETE WHICH HAS ENABLED A DATABASE TO BE CREATED FROM REGISTRY DATA FROM THREE ACADEMIC INSTITUTIONS AND TWO NIH STUDIES. IT CONTAINS LONGITUDINAL DATA ON OVER 3300 PKD PATIENTS. THE DATA HAS BEEN ANALYZED AND A BRIEFING PACKAGE WAS SUBMITTED TO BOTH THE FDA AND EMA. FINAL QUALIFICATION PACKAGES HAVE BEEN SUBMITTED TO THE FDA AND EMA AND THE CONSORTIUM IS WAITING FOR FINAL APPROVAL. THE MULTIPLE SCLEROSIS OUTCOME ASSESSMENT CONSORTIUM COLLABORATION HAS DEVELOPED AND PUBLISHED A NEW CDISC DATA STANDARD FOR MS AND HAVE CREATED AN MS DATABASE. APPROXIMATELY 5,000 PATIENT RECORDS HAVE BEEN LOADED AND 16,000 ARE EXPECTED EVENTUALLY. WORK IS ONGOING TO DEVELOP AND QUALIFY A NEW IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT WITH THE FDA AND EMA FOR USE IN NEW CLINICAL TRIALS. TEN PHARMACEUTICAL COMPANIES ARE PARTICIPATING. AN INITIAL BRIEFING PACKAGE HAS BEEN SUBMITTED TO BOTH THE FDA AND EMA. 6437786 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 34 0 1 42 1 0 0 0 0 0 0 0 0 0 0 X 13 12 1 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AZ X STEVE BROADBENT 5206478382 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 857185898 J LYLE BOOTMAN PHD SCD BOARD MEMBER 1.00 X 0 0 0 D CRAIG BRATER MD BOARD MEMBER 1.00 X 0 0 0 M WAINRIGHT FISHBURN JR BOARD MEMBER 1.00 X 0 0 0 HON JAMES C GREENWOOD BOARD MEMBER 1.00 X 0 0 0 MICHAEL KASSER MBA PHD BOARD MEMBER 1.00 X 0 0 0 SHAUN A KIRKPATRICK MA BOARD MEMBER 1.00 X 0 0 0 HON JAMES T KOLBE BOARD MEMBER 1.00 X 0 0 0 RICHARD T MYERS JR BOARD MEMBER 1.00 X 0 0 0 CINDY PARSEGHIAN BOARD MEMBER 1.00 X 0 0 0 ALASTAIR JJ WOOD MB CHB BOARD MEMBER 1.00 X 0 0 0 PETER B CORR MD PHD CHAIRMAN OF THE BOARD 1.00 X X 0 0 0 JEFFREY E JACOB SM VICE CHAIRMAN 1.00 X X 0 0 0 CAROLYN COMPTON MD PHD PRESIDENT & CEO 40.00 X X 84130 0 6718 MARTHA BRUMFIELD PHD PRESIDENT & CEO 40.00 X X 256061 0 20309 JOYCE ROGERS CMA MBA CHIEF FINANCIAL OFFICER 40.00 X 83128 0 8792 STEVEN BROADBENT MBA TREASURER & COO 40.00 X 178041 0 24332 LYNN D HUDSON PHD EXECUTIVE DIRECTOR 40.00 X 182384 0 16648 STEPHEN JOEL COONS PHD EXECUTIVE DIRECTOR 40.00 X 168196 0 19577 DEBRA HANNA PHD EXECUTIVE DIRECTOR 40.00 X 153317 0 21297 DIANE STEPHENSON PHD EXECUTIVE DIRECTOR 40.00 X 152591 0 21994 KLAUS ROMERO MD MS DIRECTOR, PHARMAMETRICS 40.00 X 147507 0 13937 1405355 0 153604 11 0 1 0 PHARSIGHT CORPORATION 210 N TUCKER STE 350 ST LOUIS MO 63101 CONSULTING 334317 HEALTH RESEARCH ASSOCIATES 6505 216TH STREET SW SUITE 105 MOUNTLAKE TERRACE WA 98043 RESEARCH 315277 ADELPHI VALUES 290 CONGRESS STREET BOSTON MA 02210 RESEARCH 267827 CDISC PO BOX 2068 ROUND ROCK TX 78680 CONSULTING 160609 RTI HEALTH SOLUTIONS 200 PARK OFFICES DRIVE RESEARCH TRIANGLE PARK NC 27709 RESEARCH 139277 8 2760778 2610004 5370782 RESEARCH SUPPORT FEES 541700 2865434 2865434 OTHER REVENUE 900099 141827 141827 3007261 17632 17632 52598 0 52598 52598 52598 1105 32563 -31458 -31458 -31458 8416815 3007261 0 38772 X 293808 293808 536993 348913 188080 2818073 2009647 808426 213167 152888 60279 229966 168015 61951 228856 161595 67261 75315 74970 345 121736 85958 35778 60221 42522 17699 2069108 1987193 45411 36504 89000 62843 26157 159452 131490 27962 110091 102464 7627 338230 203655 134575 282612 268460 14152 260303 236561 6042 17700 86954 61398 25556 34650 24466 10184 DUES AND SUBSCRIPTIONS 18195 14664 3531 MISCELLANEOUS 8130 6276 1854 8034860 6437786 1542870 54204 1387790 2377814 3572128 8050439 371966 556585 730459 677052 59428 38074 896672 733272 176191 163400 2403428 3374261 15471 15471 8716861 15253096 647230 572234 4558010 10787286 5205240 11359520 X 3457126 3877914 54495 15662 3511621 3893576 8716861 15253096 381955 0 X 0 1 X 1 1 1 X 5617050 7857830 7998908 5915630 5370782 32760200 5617050 7857830 7998908 5915630 5370782 32760200 1976012 30784188 30965 34431 22660 21279 70230 179565 41243 30697 20745 92685 33032450 11871007 0.93190 0.97690 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 60221 60221 7974639 8034860 551743 137936 0 0 630748 670322 617482 551743 2470295 3705443 108886 109805 60071 60221 338983 157687 167581 154371 137936 617575 926363 171507 108702 62805 249206 218796 30410 475959 405774 70185 163400 X 8448273 0 8448273 -31458 -31458 8416815 8066318 31458 31458 8034860 0 8034860 PART X, LINE 2: FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. ACCORDINGLY, NO PROVISION FOR FEDERAL AND STATE INCOME TAXES IS MADE IN THE FINANCIAL STATEMENTS. INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). GAAP REQUIRES MANAGEMENT TO PERFORM AN EVALUATION OF ALL TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE COURSE OF PREPARING C-PATH'S TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS MEET A "MORE LIKELY THAN NOT" STANDARD OF BEING SUSTAINED UNDER EXAMINATION BY THE APPLICABLE TAXING AUTHORITIES. THIS EVALUATION IS REQUIRED TO BE PERFORMED FOR ALL OPEN TAX YEARS, AS DEFINED BY THE VARIOUS STATUTES OF LIMITATIONS, FOR FEDERAL AND STATE PURPOSES. C-PATH IS ONLY SUBJECT TO INCOME TAXES ON UBTI AS APPLICABLE. AS A RESULT, C-PATH IS REQUIRED TO FILE INFORMATIONAL RETURNS FOR FEDERAL AND STATE PURPOSES AND, IF IT HAS UBTI, FEDERAL AND STATE INCOME TAX RETURNS. WITH LIMITED EXCEPTIONS, C-PATH IS NO LONGER SUBJECT TO TAX EXAMINATION FOR ANY YEARS EARLIER THAN 2011 FOR FEDERAL AND 2010 FOR STATE. MANAGEMENT HAS PERFORMED ITS EVALUATION OF TAX POSITIONS TAKEN ON ALL OPEN TAX RETURNS AND HAS DETERMINED THAT THERE WERE NO POSITIONS TAKEN THAT DO NOT MEET THE "MORE LIKELY THAN NOT" STANDARD. PART XI, LINE 4B - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF ASSET -31,458. PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF ASSET 31,458. 1 INSTITUTE ON SCIENCE FOR GLOBAL POLICY 3320 N CAMPBELL AVE SUITE 200 TUCSON AZ 85719 453998749 501(C)(3) 100832 CPATH ACTED AS FISCAL SPONSOR WHILE ISGP OBTAINED TAX EXEMPT STATUS UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 STATE OF TEXAS 24313 RESEARCH FOR CPTR CONSORTIUM UNIVERSITY OF CALIFORNIA 1855 FOLSOM STREET BOX 0897 SAN FRANCISCO CA 94143 946036493 STATE OF CALIFORNIA 128425 TO DEVELOP A TUBERCULOSIS DISEASE-DRUG PHYSIOLOGICALLY-BASED SYSTEMS PHARMACOLOGY PLATFORM. UNIVERSITY OF FLORIDA PO BOX 113001 GAINSVILLE FL 32611 596002052 STATE OF FLORIDA 31010 TO DEVELOP A POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL FOR TUBERCULOSIS. 4 0 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. X X X X X X 0 0 0 0 0 0 0 0 0 MARTHA BRUMFIELD PHD PRESIDENT & CEO 256061 0 0 0 0 0 17375 0 2934 0 276370 0 0 0 STEVEN BROADBENT MBA TREASURER & COO 178041 0 0 0 0 0 14544 0 9788 0 202373 0 0 0 LYNN D HUDSON PHD EXECUTIVE DIRECTOR 182384 0 0 0 0 0 14544 0 2104 0 199032 0 0 0 STEPHEN JOEL COONS PHD EXECUTIVE DIRECTOR 168196 0 0 0 0 0 13736 0 5841 0 187773 0 0 0 DEBRA HANNA PHD EXECUTIVE DIRECTOR 153317 0 0 0 0 0 12360 0 8937 0 174614 0 0 0 DIANE STEPHENSON PHD EXECUTIVE DIRECTOR 152591 0 0 0 0 0 12360 0 9634 0 174585 0 0 0 KLAUS ROMERO MD MS DIRECTOR, PHARMAMETRICS 147507 0 0 0 0 0 4457 0 9480 0 161444 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 J. LYLE BOOTMAN IS A DIRECTOR AND SHAUN A. KIRKPATRICK IS BOTH AN OFFICER AND DIRECTOR OF RESEARCH CORPORATION TECHNOLOGIES, INC. FORM 990, PART VI, SECTION A, LINE 4 THE BYLAWS WERE AMENDED ON OCTOBER 21, 2013 FOR THE FOLLOWING CHANGES: REVISIONS TO SPECIFY THE PROCESS FOR NEW BOARD MEMBER ELECTIONS, THE MEANS TO DETERMINE THE SIZE OF THE BOARD, THE CREATION OF EMERITUS DIRECTORS AND FLEXIBILITY ON THE DATE OF THE ANNUAL MEETING. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S ACCOUNTING ASSOCIATE, COO, PRESIDENT/CEO, AN OUTSIDE CPA, THE BOARD AUDIT COMMITTEE AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS AND DIRECTORS MUST FILL OUT CONFLICT OF INTEREST DISCLOSURES ANNUALLY. EMPLOYEES COMPLETE THE CONFLICT OF INTEREST FORM UPON HIRING AND UPDATE THE DOCUMENT AS NEEDED. EMPLOYEES ARE REMINDED ANNUALLY TO REVIEW THEIR STATUS. THESE DISCLOSURES ARE REVIEWED BY THE PRESIDENT/CEO, THE COO AND THE BOARD AUDIT COMMITTEE. FORM 990, PART VI, SECTION B, LINE 15 A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. EVERY FEW YEARS THE COMMITTEE SEEKS AN INDEPENDENT COMPENSATION CONSULTING ORGANIZATION. AFTER THE CONSULTING ORGANIZATION HAS BEEN RETAINED, THE COMPENSATION COMMITTEE RECEIVES THE CONSULTANT'S EXECUTIVE COMPENSATION REVIEWS AND RECOMMENDATIONS. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/CEO. THE LAST INDEPENDENT COMPENSATION SURVEY WAS CONDUCTED FOR THE CEO IN AUGUST 2011. FORM 990, PART VI, SECTION C, LINE 19 ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. FORM 990, PART IX, LINE 11G RESEARCH SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 1,359,518. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,359,518. CONSULTING: PROGRAM SERVICE EXPENSES 573,668. MANAGEMENT AND GENERAL EXPENSES 39,563. FUNDRAISING EXPENSES 36,504. TOTAL EXPENSES 649,735. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 54,007. MANAGEMENT AND GENERAL EXPENSES 5,848. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 59,855. THE CRITICAL PATH FOUNDATION 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 85718 204780896 RAISING AND CONTRIBUTING FUNDS TO CRITICAL PATH INSTITUTE AZ 501(C)(3) 11 CRITICAL PATH INSTITUTE 1 CRITICAL PATH GLOBAL LTD 20-22 BEDFORD ROW LONDON UK WC1R 4JS FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY UK CRITICAL PATH INSTITUTE 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0